Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Journal of Cell Biology

Volumn 134, Issue 6, 1996, Pages 1563-1571

  Deng, Gang ^a   Curriden, Scott A ^a   Wang, Soujuan ^a   Rosenberg, Steven ^b   Loskutoff, David J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SECRETION; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INDUCTION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE SWITCHING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029816265     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.134.6.1563     Document Type: Article

References (61)

1. Andreasen, P.A., L.S. Nielsen, P. Kristensen, J. Grondahl-Hansen, L. Skriver, and K. Dano. 1986. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 261:7644-7651.
2. Behrendt, N., E. Ronne, and K. Dano. 1995. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol. Chem. Hoppe-Seyler. 376:269-279.
3. Bernfield, M.R., M.T. Hinkes, and R.L. Gallo. 1993. Developmental expression of the syndecans: possible function and regulation. Development. 119:205-212.
4. Boukerche, H., M. Benchaibi, O. Berthier-Vergnes, G. Lizard, M. Bailly, and J.L. McGregor. 1994. Two human melanoma cell-line variants with enhanced in vivo tumor growth and metastatic capacity do not express the β 3 integrin subunit. Eur. J. Biochem. 220:485-491.
5. Chen, W.T. 1992. Membrane proteases: roles in tissue remodeling and tumour invasion. Curr. Opin. Cell Biol. 4:802-809.
6. Ciambrone, G.J., and P.J. McKeown-Longo. 1992. Vitronectin regulates the synthesis and location of urokinase-type plasminogen activator in HT-1080 cells. J. Biol. Chem. 267:13617-13622.
7. Cohen, R.L., X.-P. Xi, C.W. Crowley, B.K. Lucas, A.D. Levinson, and M.A. Shuman. 1991. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells. Blood. 78:479-487.
8. Cubellis, M.V., P. Andreasen, P. Ragno, M. Mayer, K. Dano, and F. Blasi. 1989. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA. 86:4828-4832.
9. Cubellis, M.V., T.-C. Wun, and F. Blasi. 1990. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO (Eur. Mol. Biol. Organ.) J. 9:1079-1085.
10. Dano, K., P.A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L.S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 44:139-266.
11. Declerck, P.J., M. De Mol, M.C. Alessi, S. Baudner, E.P. Paques, K.T. Preissner, G.M. Berhaus, and D. Collen. 1988. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J. Biol. Chem. 30:15454-15461.
12. Del Vecchio, S., M.P. Stoppelli, M.V. Carriero, R. Fonti, O. Massa, P.Y. Li, G. Botti, M. Cerra, G. D'Aiuto, G. Esposito, and M. Salvatore. 1993. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res. 53:3198-3206.
13. Delbaldo, C., M. Cunningham, J.-D. Vassalli, and A.-P. Sappino. 1995. Plasmin-catalyzed proteolysis in colorectal neoplasia. Cancer Res. 55:4688-4695.
14. Deng, G., G. Royle, D. Seiffert, and D. Loskutoff. 1995. The PAI-1/vitronectin interaction: two cats in a bag? Thromb. Haemostasis. 74:66-70.
15. Deng, G., G. Royle, S. Wang, K. Crain, and D.J. Loskutoff. 1996. Structural and functional analysis of the PAI-1 binding motif in the somatomedin B domain of vitronectin. J. Biol. Chem. 271:12716-12723.
16. Estreicher, A., J. Mühlhauser, J.-L. Carpentier, L. Orci, and J.-D. Vassalli. 1990. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111:783-792.
17. Gladson, C.L., V. Pijuan-Thompson, M.A. Olman, G.Y. Gillespie, and I.Z. Yacoub. 1995. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am. J. Pathol. 146:1150-1160.
18. Goodson, R.J., M.V. Doyle, S.E. Kaufman, and S. Rosenberg. 1994. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA. 91:7129-7133.
19. Grondahl-Hansen, J., I.J. Christensen, C. Rosenquist, N. Brunner, H.T. Mouridsen, K. Dano, and M. Blichert-Toft. 1993. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:2513-2521.
20. Gumbiner, B.M. 1996. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell Press. 84:345-357.
21. Hauptmann, S., C. Denkert, H. Lohrke, L. Tietze, S. Ott, B. Klosterhalfen, and C. Mittermayer. 1995. Integrin expression on colorectal tumor cells growing as monolayers, as multicellular tumor spheroids, or in nude mice. Int. J. Cancer. 61:819-825.
22. He, C.S., S.M. Wilhelm, A.P. Pentland, B.L. Marmer, G.A. Grant, A.Z. Eisen, and G.I. Goldberg. 1989. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. USA. 86:2632-2636.
23. Heiss, M.M., R. Babic, H. Allgayer, K.U. Greutzner, K.-W. Jauch, U. Loehrs. and F.W. Schildberg. 1995. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. 13:2084-2093.
24. Howlett, A.R., N. Bailey, C. Damsky, O.W. Petersen, and M.J. Bissell. 1995. Cellular growth and survival are mediated by β 1 integrins in normal human breast epithelium but not in breast carcinoma. J. Cell Sci. 108:1945-1957.
25. Huarte, J., D. Belin, and J.-D. Vassalli. 1985. Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell. 43:551-558.
26. Hynes, R.O., and A.D. Lander. 1992. Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell. 68:303-322.
27. Jenne, D., and K.K. Stanley. 1985. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO (Eur. Mol. Biol. Organ.) J. 4:3153-3157.
28. Kaufman, S.E., S. Brown, and G.B. Stauber. 1993. Characterization of ligand binding to immobilized biotinylated extracellular domains of three growth factor receptors. Anal. Biochem. 211:261-266.
29. Knudsen, B.S., P.C. Hapel, and R.L. Nachman. 1987. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J. Clin. Invest. 80:1082-1089.
30. Kobayashi, H., S. Fujishiro, and T. Terao. 1994. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 54:6539-6548.
31. Kruithof, E.K.O. 1988. Plasminogen activator inhibitors - a review. Enzyme. 40:113-121.
32. Kuhn, W., L. Pache, B. Schmalfeldt, P. Dettmar, M. Schmitt, F. Janicke, and H. Graeff. 1994. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55:401-409.
33. Liu, G., M.A. Shuman, and R.L. Cohen. 1995. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer. 60:501-506.
34. Loskutoff, D.J. 1991. Regulation of PAI-1 gene expression. Fibrinolysis. 5:197-206.
35. Mignatti, P., and D.B. Rifkin. 1993. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:161-195.
36. Mimuro, J., and D.J. Loskutoff. 1989. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J. Biol. Chem. 264:5058-5063.
37. Nekarda, H., M. Schmitt, K. Ulm, A. Wenninger, H. Vogelsang, K. Becker, J.D. Roder, U. Fink, and J.R. Siewert. 1994. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Can. Res. 54:2900-2907.
38. Nesbit, M., and M. Herlyn. 1994. Adhesion receptors in human melanoma progression. Invasion Metastasis. 14:131-146.
39. Pappot, H., H. Gårdsvoll, J. Romer, A. Navrsted Pedersen, J. Grondahl-Hansen, C. Pyke, and N. Brünner. 1995. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe-Seyler. 376:259-267.
40. Pedersen, H., N. Brunner, D. Francis, K. Osterlind, E. Ronne, H.H. Hansen, K. Dano, and J. Grondahl-Hansen. 1994. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54:4671-4675.
41. Ploug, M., E. Ronne, N. Behrendt, A.L. Jensen, F. Blasi, and K. Dano. 1991. Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J. Biol. Chem. 266:1926-1933.
42. Ploug, M., V. Ellis, and K. Dano. 1994. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-Anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry. 33:8991-8997.
43. Plow, E.F., T. Herren, A. Redlitz, L.A. Miles, and J.L. Hoover-Plow. 1995. The cell biology of the plasminogen system. FASEB (Fed. Am. Soc. Exp. Biochem.) J. 9:939-945.
44. Prendergast, G.C., and M.D. Cole. 1989. Posttranscriptional regulation of cellular gene expression by the c-myc oncogene. Mol. Cell. Biol. 9:124-134.
45. Quax, P.H.A., G.N.P. van Muijen, E.J.D. Weening-Verhoeff, L.R. Lund, K. Dano, D.J. Ruiter, and J.H. Verheijen. 1991. Metastatic behavior of human melanoma cell lines in nude mice correlated with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell Biol. 115:191-199.
46. Roldan, A.L., M.V. Cubellis, M.T. Masucci, N. Behrendt, L.R. Lund, K. Dano, E. Appella, and F. Blasi. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO (Eur. Mol. Biol. Organ.) J. 9:467-474.
47. 1 integrin receptor in malignancy. Invasion Metastasis. 14:87-97.
48. Roussel, E., M.C. Gingras, J.Y. Ro, C. Branch, and J.A. Roth. 1994. Loss of α 1 β 1 and reduced expression of other β 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes. J. Surg. Oncol. 56:198-208.
49. Salonen, E., A. Vaheri, J. Pollanen, R. Stephens, P. Andreasen, M. Mayer, K. Dano, J. Gailit, and E. Ruoslahti. 1989. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J. Biol. Chem. 264:6339-6343.
50. Seiffert, D., G. Ciambrone, N.V. Wagner, B.B. Binder, and D.J. Loskutoff. 1994. The somatomedin B domain of vitronectin: structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J. Biol. Chem. 269:2659-2666.
51. Seiffert, D., and D.J. Loskutoff. 1991a. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J. Biol. Chem. 266:2824-2830.
52. Seiffert, D., and D.J. Loskutoff. 1991b. Kinetic analysis of the interaction between type 1 plasminogen activator inhibitor and vitronectin and evidence that the bovine inhibitor binds to a thrombin-derived amino-terminal fragment of bovine vitronectin. Biochim. Biophys. Acta. 1078:23-30.
53. Sier, C.F.M., H.J.M. Vloedgraven, S. Ganesh, G. Griffioen, P.H.A. Quax, J.H. Verheijen, G. Dooijewaard, K. Welvaart, C.J.H. Van de Velde, C.B.H.W. Lamers, et al. 1994. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology. 107:1449-1456.
54. Stratton-Thomas, J.R., H.Y. Min, S.E. Kaufman, C.Y. Chiu, G.T. Mullenbach, and S. Rosenberg. 1995. Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain. Protein Engineering. 8:463-470.
55. Van Meijer, M., and H. Pannekoek. 1995. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis. 9: 263-276.
56. Vassalli, J.D., A. Sappino, and D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88:1067-1072.
57. Waltz, D.A., and H.A. Chapman. 1994. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269:14746-14750.
58. Waltz, D.A., L.Z. Sailor, and H.A. Chapman. 1993. Cytokines induce urokinase-dependent adhesion of human myeloid cells; A regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91:1541-1552.
59. Wei, Y., D.A. Waltz, N. Rao, R.J. Drummond, S. Rosenberg, and H.A. Chapman. 1994. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:32380-32388.
60. Wiman, B., A. Almquist, O. Sigurdardottir, and T. Lindahl. 1988. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett. 242: 125-128.
61. Yatohgo, T., M. Izumi, H. Kashiwagi, and M. Hayashi. 1998. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct. 13:281-292.